Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland –on behalf of the UK national coordinating committee for breast pathology

[1]  M. Dowsett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. Provenzano,et al.  ESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. , 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  S. Parry,et al.  54P Proficiency testing for HER2-low expression in breast cancer: Results of the UK NEQAS ICC & ISH programme examining technical and interpretive accuracy , 2023, ESMO Open.

[4]  P. Westenend,et al.  Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study. , 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[5]  Huina Zhang,et al.  The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer. , 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[6]  I. Ellis,et al.  UK recommendations for HER2 assessment in breast cancer: an update , 2022, Journal of Clinical Pathology.

[7]  K. Shen,et al.  HER2-Low Status Is Not Accurate in Breast Cancer Core Needle Biopsy Samples: An Analysis of 5610 Consecutive Patients , 2022, Cancers.

[8]  C. V. van Deurzen,et al.  Real-world data of HER2-low metastatic breast cancer: A population based cohort study , 2022, Breast.

[9]  F. Ma,et al.  HER2-Low Breast Cancer: Novel Detections and Treatment Advances. , 2022, Critical reviews in oncology/hematology.

[10]  C. Denkert,et al.  Selecting patients with HER2-low breast cancer: Getting out of the tangle. , 2022, European journal of cancer.

[11]  G. Ball,et al.  Refining the definition of HER2‐low class in invasive breast cancer , 2022, Histopathology.

[12]  G. Viale,et al.  Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status , 2022, Virchows Archiv.

[13]  J. Rahnenführer,et al.  Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. , 2022, European journal of cancer.

[14]  S. Tyekucheva,et al.  Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. , 2022, JAMA oncology.

[15]  Yang Luo,et al.  Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience , 2022, Frontiers in Oncology.

[16]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[17]  Yan Song,et al.  Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer , 2022, Laboratory Investigation.

[18]  Huina Zhang,et al.  HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles , 2022, Modern Pathology.

[19]  M. Fassan,et al.  Evolution of HER2-low expression from primary to recurrent breast cancer , 2021, NPJ breast cancer.

[20]  P. Fasching,et al.  Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. , 2021, The Lancet. Oncology.

[21]  Michel E. Vandenberghe,et al.  Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay. , 2021 .

[22]  A. Lluch,et al.  Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer , 2021, NPJ breast cancer.

[23]  Laia Bernet Vegué,et al.  "HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH" Answer to the statistical issue to avoid misinterpretation. , 2020, Annals of diagnostic pathology.

[24]  A. Sapino,et al.  Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. , 2020, Seminars in cancer biology.

[25]  M. Dowsett,et al.  Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients , 2018, The journal of pathology. Clinical research.

[26]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[27]  G. Viale,et al.  An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper® , 2017, Breast Cancer Research.

[28]  C. Luchini,et al.  In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases , 2016, Virchows Archiv.

[29]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.